However, it has been suggested that the restoration of SMN-FL to normal levels in patients with SMA, even at the earliest stages of postnatal development, might not be sufficient to mitigate the whole spectrum of neurodevelopmental abnormalities associated with the disease [67]. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.